Zentalis licenses ROR1 ADC ZPC-21 to Immunome for $35M upfront, up to $275M milestones

Zentalis Pharmaceuticals, Inc.

Exclusive worldwide license of preclinical ROR1 ADC ZPC-21 and proprietary ADC platform to Immunome.
Zentalis receives $35M upfront in cash and Immunome common stock; eligible for up to $275M milestones plus mid-to-high single-digit royalties.
Immunome plans to submit IND for ZPC-21 in 1Q 2025.
Zentalis to focus resources on advancing azenosertib (WEE1 inhibitor) in multiple clinical studies.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.